1. Home
  2. JAGX vs APLM Comparison

JAGX vs APLM Comparison

Compare JAGX & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • APLM
  • Stock Information
  • Founded
  • JAGX 2013
  • APLM 2016
  • Country
  • JAGX United States
  • APLM United States
  • Employees
  • JAGX N/A
  • APLM N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • APLM Blank Checks
  • Sector
  • JAGX Health Care
  • APLM Finance
  • Exchange
  • JAGX Nasdaq
  • APLM Nasdaq
  • Market Cap
  • JAGX 7.4M
  • APLM 6.9M
  • IPO Year
  • JAGX N/A
  • APLM N/A
  • Fundamental
  • Price
  • JAGX $5.88
  • APLM $4.89
  • Analyst Decision
  • JAGX
  • APLM
  • Analyst Count
  • JAGX 0
  • APLM 0
  • Target Price
  • JAGX N/A
  • APLM N/A
  • AVG Volume (30 Days)
  • JAGX 247.5K
  • APLM 6.9K
  • Earning Date
  • JAGX 05-15-2025
  • APLM 04-03-2025
  • Dividend Yield
  • JAGX N/A
  • APLM N/A
  • EPS Growth
  • JAGX N/A
  • APLM N/A
  • EPS
  • JAGX N/A
  • APLM N/A
  • Revenue
  • JAGX $11,689,000.00
  • APLM $198,000.00
  • Revenue This Year
  • JAGX $22.41
  • APLM $415.15
  • Revenue Next Year
  • JAGX $30.00
  • APLM N/A
  • P/E Ratio
  • JAGX N/A
  • APLM N/A
  • Revenue Growth
  • JAGX 19.75
  • APLM N/A
  • 52 Week Low
  • JAGX $4.02
  • APLM $4.71
  • 52 Week High
  • JAGX $502.50
  • APLM $42.00
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 37.09
  • APLM 35.08
  • Support Level
  • JAGX $5.30
  • APLM $4.63
  • Resistance Level
  • JAGX $13.20
  • APLM $5.45
  • Average True Range (ATR)
  • JAGX 1.49
  • APLM 0.54
  • MACD
  • JAGX -0.57
  • APLM -0.10
  • Stochastic Oscillator
  • JAGX 7.30
  • APLM 16.03

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: